Introduction
Prorenin is the inactive precursor of renin (EC 3.4.23. 15 ), which is a key enzyme in the regulation of blood pressure (BP) and electrolyte balance. Prorenin has a prosegment with 43 amino acid residues attached to the N terminus of mature renin with 339-341 residues. [1] [2] [3] The prosegment has been considered to associate with mature renin to prevent interaction with angiotensinogen, its macromolecular renin substrate. [4] [5] [6] Prorenin does not proteolytically self-activate like pepsinogen, and its blood circulating level is ten times higher than that of mature renin. 7, 8 Some investigators have recently proposed that prorenin is a useful marker of diabetic microvascular complications, Wilms' tumor [9] [10] [11] and retinopathy of prematurity. 12 Prorenin studies have advanced recently to the pathophysiological fields by a series of investigations on prorenin and the (pro)renin receptor [13] [14] [15] [16] since its finding. 17 A regulatory system, 'receptor associated prorenin system', has been also proposed. 14 This report discusses the nonproteolytic activation of prorenin reported in these studies, in particular, 1) the structure and function of prorenin that is the source of investigations into the 'decoy peptide' and 2) relationship of prorenin with (pro)renin receptor in vitro and on the cell membrane.
Nonproteolytic activation of prorenin by specific antibodies
Tertiary structural information is essential to design topologically specific antibodies against prorenin. 18 Its stereo structure has been predicted by a protein modelling method based on the atomic coordinates of pepsinogen (2 psg) as shown in figure 1. 
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Renin Using various region specific antibodies against the prorenin prosegment, nonproteolytic activation of prorenin by protein-protein interaction was investigated at physiological pH. 18 Each of the antibodies was labelled anti-01/06, anti-07/10, anti-11/26, anti-16/26, and anti-27/41, respectively, for their binding specificities to the prorenin region. Inactive prorenin bound to anti-01/06, anti-11/26, and anti-27/41 antibodies with equilibrium dissociation constants of 138, 41 and 22 nM, respectively. However, the intact prorenin did not significantly bind to anti-07/10 and anti-16/26 antibodies. The prorenin (0.1 nM) was found to be nonproteolytically activated by anti-11/26 antibodies (200 nM). Prorenin was not active even under complex with either anti-01/06 or anti-27/41 antibodies. Therefore, I 11P FLKR 15P must be a key region for the nonproteolytic activation of prorenin by protein-protein interaction. On the other hand, prorenin was well known to be reversibly activated under low pH. Such acid-activated prorenin bound to anti-07/10 and anti-16/26 antibodies as well as to anti-01/06, anti-11/15, and anti-27/41 antibodies at neutral pH. Their dissociation constants were 13, 40, 8.6, 3.6 and 14 nM, respectively. The acid-activated prorenin has been shown to be re-inactivated by an increase in pH at neutral range. Anti-07/10 and anti-11/26 antibodies were found to inhibit such re-inactivation by more than 90% and 50%, respectively, although other kinds of antibodies did not prevent the re-inactivation. Demonstrating that the T 7P FKR 10P region must have an essential role for inactivation of prorenin.
From these results we have proposed that there are two key regions, the 'gate' (Thr 7P -Phe-Lys-Arg 7P ) and the 'handle' (Ile 11P -Phe-Leu-Lys-Arg 15P ) for nonproteolytic activation of human prorenin (figure 1).
(Pro)renin receptor and decoy peptide
A renin binding protein (RnBP) and the mannose 6-phosphate/IGF2 receptor (M6P/IGF2R) have been reported as an intracellular renin inhibitor and a renin/prorenin receptor, respectively. 15, 16 The RnBP localised in the cytosolic fraction of cells and contributed neither to BP control nor to regulation of plasma renin activity. The M6P/IGF2R bound to and internalised renin and prorenin but this binding did not activate prorenin. The M6P/IGF2R probably acts as a clearance receptor for renin and prorenin. 15 Recently, the (pro)renin receptor was found in human mesangial cells. 17 This receptor consists of 350 amino acid residues with a single transmembrane domain. (Pro)renin receptor bound renin as well as prorenin to activate them. Its c-terminal region associated with PLZF inner the cell side. 19 It is highly homologous in the human, mouse and rat as well as chicken, fish, xenopus and C elegans. 20 We also cloned rat (pro)renin receptor complementary desoxyribonucleic acid (cDNA) (AB188298 in DDJB) to investigate non-proteolytic activation of rat prorenin by binding to the rat (pro)renin receptor in vitro and on the membrane. The rat recombinant (pro)renin receptor was expressed in a baculovirus expression system 21 and prepared from the cytoplasmic fraction of the insect cells. Prorenin as well as renin bound to the receptor with different binding affinities. Their equilibrium dissociation constants values were estimated at approximately 8.0 and 20 nM, respectively. Prorenin, which is present in the blood at a concentration ten times higher than renin, has higher affinity for the receptor than renin. Rat prorenin was also activated by binding to the receptor. The receptor can be, therefore, regarded as a prorenin receptor rather than a renin receptor in the physiological aspect. On the other hand, renin kept activity at a similar level, even after the binding. The K m of their complexes was the same at 3.3 μM when sheep angiotensinogen was used as the substrate. Their V max values were 1.7 and 10 nM·h -1 , respectively. From these, rat prorenin as well as renin was observed to bind to the recombinant receptor and express the catalytic activity in vitro.
The rat (pro)renin receptor was also expressed on the membranes of COS-7 cell in a dose-and time-dependent manner, and the highest amount of the receptor was observed after 18 hours transfection of vector with the cDNA. Ninety percent of the total rat prorenin at 2.0 nM was bound to the receptor. Its K d was 0.89 nM, which was much lower than that obtained by the in vitro experiment. The K m values for renin and prorenin bound to the receptor were in the similar range of 1.0 μM when sheep angiotensinogen was used as a substrate. The K m value of mature rat renin in the soluble phase was also 1.0 μM. On the other hand, the prorenin bound to receptor on the membrane had
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Figure 2
The amino acid sequences of the decoy peptide in human, rat and mouse and possibly its inhibition mechanism of prorenin binding to the (pro)renin receptor. higher Vmax (15 nM·h -1 ) than that of mature renin bound to the receptor (1.5 nM·h -1 ). As for the relationship of these V max values, it is opposite to that obtained by the in vitro experiment. Some specific macromolecules may stabilise the prorenin-receptor complex on the membrane.
The rat and mouse decoy peptides (Arg-Ile-Leu-Leu-Lys-Lys-Met-Pro-Ser-Val and Arg-Ile-Pro-Leu-Lys-Lys-Met-Pro-Ser-Val, respectively, figure 2) were designed on the basis of predicted tertiary structure of human prorenin and sequences of those handle regions (Ile-Leu-Leu-Lys-Lys and Ile-Pro-Leu-Lys-Lys, respectively) for animal experiments. These peptides are useful as indicated in the recent reviews. [15] [16] [17] The rat decoy as well as handle region peptide actually inhibited the rat prorenin binding to the rat (pro)renin receptor on the membrane of COS-7. 22 Their K i values were similar in the range around 7 nM. Therefore, the 'handle' region probably also plays a crucial role in the prorenin binding to (pro)renin receptor in vivo.
Conclusions
As described previously in the Renin Report (Issues 2 and 6) and other reviews, 15-17 a lot of data on the (pro)renin receptor obtained by animal experiments have indicated that the decoy peptide prevents diabetes nephropathy and retinopathy, and proposes the existence of a novel regulative system that stimulates another signal transduction as well as that of renin angiotensin system. These must be a clue to advance a useful drug design with greater benefit on the end-organ damage in diabetes and hypertension than conventional renin angiotensin system inhibitors.
Terminology of renin/prorenin receptor: In the first international symposium on renin/prorenin receptor (URL: http://www2.eur.nl/fgg/pharm/ symposium/introduction.html) held in Fukuoka, 2006, the agreed name is the (pro)renin receptor.
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